Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals
NCT07712042
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Hyperlipidemia
Interventions
DRUG:
Tafolecimab
Sponsor
Mei Gao